Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01295112 · ClinicalTrials.gov registry record · Phase 2
Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion
A Phase 2 study, sponsored by Texas Retina Associates.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT01295112: Completed Phase 2 study, sponsored by Texas Retina Associates.
NCT01295112 is a Phase 2 study that has completed, run by Texas Retina Associates. The registered enrollment target is 68 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (49% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01295112, a Phase 2 study, has completed, sponsored by Texas Retina Associates.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
This is a study designed to determine if the addition of Ozurdex® to bevacizumab (Avastin®) eye injections reduces the need for repeat bevacizumab eye injections in patients with nonischemic central retina vein occlusion.
Interventions
- DRUG Active bevacizumab and Sham dexamethasone
- DRUG Active bevacizumab and Active dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2011-05 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
What the finished NCT01295112 record still lists
NCT01295112 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (49% lower).
The record links to 0 conditions, and to 2 interventions - of which Active bevacizumab and Sham dexamethasone is the first listed.
NCT01295112 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01295112 about?
NCT01295112 is a clinical study titled "Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion". This is a study designed to determine if the addition of Ozurdex® to bevacizumab (Avastin®) eye injections reduces the need for repeat bevacizumab eye injections in patients with nonischemic central retina vein occlusion.
What is the current status of trial NCT01295112?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2011-05. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01295112?
The interventions under investigation include: Active bevacizumab and Sham dexamethasone (DRUG), Active bevacizumab and Active dexamethasone (DRUG).
Who is sponsoring clinical trial NCT01295112?
This trial is sponsored by Texas Retina Associates, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01295112's enrollment target sits among peer trials
68 967th of 2000 higher than 1,027 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia